Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front‐line regimens using the SEER‐Medicare data
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Medicine"
DOI: 10.1002/cam4.2698
Abstract: The landscape of treatment for multiple myeloma (MM) has significantly changed over the last decade due to novel agents that have shown superiority in efficacy such as proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) over… read more here.
Keywords: systemic therapies; utilization; medicare data; seer medicare ... See more keywords
Brief Report: Gender and Age of Diagnosis Time Trends in Children with Autism Using Australian Medicare Data
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Autism and Developmental Disorders"
DOI: 10.1007/s10803-018-3609-7
Abstract: Recent evidence suggests the male predominance in Autism Spectrum Disorder (ASD) may be decreasing. Secondary analyses of Australian Medicare data (paediatrician/child psychiatrist items for diagnosing ASD before age 13) were used (N = 73,463 unique children from… read more here.
Keywords: medicare data; autism; age; males females ... See more keywords
Real-world economic outcomes among patients (pts) who initiated sunitinib or pazopanib as first targeted therapy (TT) for advanced renal cell carcinoma (aRCC): A retrospective analysis of Medicare data.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.6_suppl.475
Abstract: 475Background: Evidence on economic outcomes could provide insight on comparative economic benefit of TTs. This study assessed all-cause healthcare resource utilization (HRU) and costs among aRCC patients who initiated pazopanib and sunitinib, two commonly-used first… read more here.
Keywords: pazopanib first; medicare data; sunitinib pazopanib; initiated sunitinib ... See more keywords